Log in

TSE:AUP - Aurinia Pharmaceuticals Stock Price, Forecast & News

C$23.98
-0.48 (-1.96 %)
(As of 02/28/2020 06:19 AM ET)
Today's Range
C$22.75
Now: C$23.98
C$24.44
50-Day Range
C$23.21
MA: C$25.46
C$27.04
52-Week Range
C$4.70
Now: C$23.98
C$28.59
Volume79,351 shs
Average Volume145,327 shs
Market CapitalizationC$2.62 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
CUSIPN/A
CIKN/A
Phone+1-250-7084272

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$318,000.00
Cash FlowC$1.43 per share
Book ValueC$1.31 per share

Profitability

Miscellaneous

Employees39
Market CapC$2.62 billion
Next Earnings Date3/17/2020 (Estimated)
OptionableNot Optionable

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News headlines about AUP stock have been trending positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aurinia Pharmaceuticals.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Neil Solomons M.D., Chief Medical Officer

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUP stock can currently be purchased for approximately C$23.98.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of C$2.62 billion and generates C$318,000.00 in revenue each year. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel